Comparative Effectiveness and Safety of Pertuzumab and Trastuzumab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy for Treatment of Metastatic Breast Cancer.

ABSTRACT:

Importance

To date, limited studies have examined the comparative outcomes of pertuzumab treatment in the real-world setting. End-of-study analyses of the CLEOPATRA trial found median overall survival (OS) of 57.1 months in patients receiving pertuzumab compared with 40.8 months in control patients, a benefit of 16.3 months. However, studies examining the real-world use of pertuzumab have found conflicting results.

Objective

To assess the real-world comparative effectiveness and safety of pertuzumab, trastuzumab, and chemotherapy for patients with metastatic breast cancer in Ontario, Canada.

Design, setting, and participants

A population-based retrospective comparative effectiveness research study was conducted. Patients receiving first-line treatments for metastatic

SUBMITTER: Dai WF 

PROVIDER: S-EPMC8886524 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature